2025
An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay.
Spigel D, Westeel V, Anderson I, Greillier L, Guisier F, Bylicki O, Badin F, Rousseau-Bussac G, Deldycke C, Griesinger F, Bograd A, Zhong W, Gubens M, Crowley J, von der Leyen H, Woodard G, Kratz J, Jablons D, Mann M. An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay. Journal Of Clinical Oncology 2025, 43: lba8027-lba8027. DOI: 10.1200/jco.2025.43.17_suppl.lba8027.Peer-Reviewed Original ResearchNon-small cell lung cancerDisease free survivalModified intent-to-treatAdjuvant chemotherapyCell lung cancerLung cancerInterim analysisCycles of platinum-based adjuvant chemotherapyNon-squamous non-small cell lung cancerEarly-stage non-small cell lung cancerRandomized trials of adjuvant chemotherapyModified intent-to-treat populationTumor size > 4 cmNon-squamous NSCLC patientsRandomized to adjuvant chemotherapyTime of chemotherapy initiationMedian disease free survivalImproved disease free survivalPlatinum-based adjuvant chemotherapyTrials of adjuvant chemotherapyHigh riskRandomized to observationMedian Follow-UpPrimary lung cancerProspective randomized trialsFive-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial.
Felip E, Altorki N, Zhou C, Vallières E, Csoszi T, Vynnychenko I, Goloborodko O, Rittmeyer A, Reck M, Martinez-Marti A, Kenmotsu H, Chen Y, Chella A, Sugawara S, Fu C, Ballinger M, Deng Y, Srivastava M, Bennett E, Gitlitz B, Wakelee H. Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial. Journal Of Clinical Oncology 2025, jco2401681. PMID: 40446184, DOI: 10.1200/jco-24-01681.Peer-Reviewed Original ResearchNon-small cell lung cancerDisease-free survivalPD-L1 TCCell lung cancerOverall survivalAdjuvant chemotherapySurvival outcomesResected stage IB-IIIA non-small cell lung cancerStage IB-IIIA non-small cell lung cancerTumor cellsResected non-small cell lung cancerFollow-upLung cancerFive-year survival outcomesStratified hazard ratioPlatinum-based chemotherapyStage II-IIIAPhase III trialsReport survival outcomesIntention-to-treatStratified HROpen-labelIII trialsAtezolizumabChemotherapyHepatoblastoma: Comprehensive Review With Recent Updates.
Jiao J, Saxena R, Morotti R. Hepatoblastoma: Comprehensive Review With Recent Updates. Advances In Anatomic Pathology 2025 PMID: 40178831, DOI: 10.1097/pap.0000000000000495.Peer-Reviewed Original ResearchRisk stratificationLiver tumorsChildren's Hepatic tumors International CollaborationPrimary malignant liver tumorsMalignant rhabdoid tumorMalignant liver tumorsPediatric liver tumorsRare pediatric liver tumorImprove risk stratificationRisk stratification algorithmChemotherapeutic regimenComplete resectionAdjuvant chemotherapyRhabdoid tumorPretreatment extentHistological heterogeneityHistological classificationHistological featuresHepatocellular neoplasmsDisease stageHepatoblastomaTumorImproved efficacyStratification algorithmReduced toxicityLoss of GATA2 Promotes Invasion and Predicts Cancer Recurrence and Survival in Uterine Serous Carcinoma
Polaki U, Gilpin T, Patil A, Chiu E, Baker R, Liu P, Pavletich T, Seifi M, Mañán-Mejías P, Morrissey J, Port J, Schwartz R, Ong I, El-Rayes D, Khalifa M, Hui P, Horner V, Virumbrales-Muñoz M, Erickson B, Barroilhet L, McGregor S, Bresnick E, Matson D. Loss of GATA2 Promotes Invasion and Predicts Cancer Recurrence and Survival in Uterine Serous Carcinoma. JCI Insight 2025, 10: e187073. PMID: 40168074, PMCID: PMC12128953, DOI: 10.1172/jci.insight.187073.Peer-Reviewed Original ResearchConceptsUterine serous carcinomaTreatment-related morbidityStudent's t-testSerous carcinomaAdjuvant chemotherapyPrimary uterine serous carcinomaUterine serous carcinoma cellsIncreased invasiveness in vitroStage I USCRecurrence-free survivalCox proportional hazard ratiosCancer-related survivalDepartment of ObstetricsKaplan-Meier methodFisher's exact testDepartment of PathologyProportional hazard ratiosRisk-stratified approachPersonalized medicine approachPredicting cancer recurrenceConfirmatory Western blotT-testClinicopathological metricsRecurrence-freeAmerican Cancer SocietyClinical Implications of Breast Cancer Intrinsic Subtypes
Rios-Hoyo A, Shan N, Karn P, Pusztai L. Clinical Implications of Breast Cancer Intrinsic Subtypes. Advances In Experimental Medicine And Biology 2025, 1464: 435-448. PMID: 39821037, DOI: 10.1007/978-3-031-70875-6_21.Peer-Reviewed Original ResearchConceptsBasal-like cancersBreast cancerDistant recurrenceLuminal cancersEndocrine therapyAdjuvant chemotherapyClinical behaviorOncotype DX recurrence scorePathologic complete response rateTreated with preoperative chemotherapyExcellent long-term survivalRisk of early recurrenceBasal-like breast cancerBreast cancer intrinsic subtypesHER2-enriched cancersImmunotherapy to chemotherapyLuminal A cancersComplete response rateImmune checkpoint inhibitorsEstrogen receptor-negativeHER2-Targeted TherapyEstrogen receptor-positiveLevel of immune infiltrationHER2 gene amplificationAdjuvant endocrine therapy
2024
The evolving landscape of adjuvant therapy in T1-T2N0 resected non-small cell lung cancer: a narrative review
Zolfaghari E, Dhanasopon A, Woodard G. The evolving landscape of adjuvant therapy in T1-T2N0 resected non-small cell lung cancer: a narrative review. Journal Of Thoracic Disease 2024, 0: 0-0. PMID: 39831209, PMCID: PMC11740046, DOI: 10.21037/jtd-24-245.Peer-Reviewed Original ResearchNon-small cell lung cancerEpidermal growth factor receptorEarly-stage non-small cell lung cancerAnaplastic lymphoma kinaseAdjuvant therapyCell lung cancerEarly-stage patientsSurgical resectionOverall survivalAdjuvant chemotherapyLung cancerSurvival benefit of adjuvant therapyAdjuvant platinum-based chemotherapyBenefit of adjuvant therapyHigh-risk pathologic featuresStage IB tumorsNational Clinical Trials RegistryPlatinum-based chemotherapyHigh-risk featuresCirculating tumor DNALandscape of adjuvant therapyLung cancer recurrenceGrowth factor receptorClinical Trials RegistryAdjuvant osimertinibTargeted Dynamic Phospho-Proteogenomic Analysis of Gastric Cancer Cells Suggests Host Immunity Provides Survival Benefit
Kume K, Iida M, Iwaya T, Yashima-Abo A, Koizumi Y, Endo A, Wade K, Hiraki H, Calvert V, Wulfkuhle J, Espina V, Siwak D, Lu Y, Takemoto K, Suzuki Y, Sasaki Y, Tokino T, Petricoin E, Liotta L, Mills G, Nishizuka S. Targeted Dynamic Phospho-Proteogenomic Analysis of Gastric Cancer Cells Suggests Host Immunity Provides Survival Benefit. Molecular & Cellular Proteomics 2024, 23: 100870. PMID: 39461475, PMCID: PMC11621936, DOI: 10.1016/j.mcpro.2024.100870.Peer-Reviewed Original ResearchDNA-damaging drugsTotal lymphocyte countCell linesResistance to DNA damaging drugsPD-L1Adjuvant chemotherapyProtein dynamicsProtein-level regulationSurvival benefitCopy number lossExpression time courseGastric cancerRelapse-free survival rateGastric cancer cellsHost immunityAssociated with prolonged survivalIncreased STAT1 phosphorylationResistance to other drugsGlobal protein dynamicsImmune checkpoint blockadePD-L1 positivityPD-L1 expressionAdvanced gastric cancerExpression of STAT1Molecular targeted drugsFinal analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]
de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman D, Colleoni M, Roylance R, Kelly C, Lombard J, El-Abed S, Choudhury A, Korde L, Vicente M, Chumsri S, Rodeheffer R, Ellard S, Wolff A, Holtschmidt J, Lang I, Untch M, Boyle F, Xu B, Werutsky G, Tujakowski J, Huang C, Baruch N, Bliss J, Ferro A, Gralow J, Kim S, Kroep J, Krop I, Kuemmel S, McConnell R, Moscetti L, Knop A, van Duijnhoven F, Gomez H, Cameron D, Di Cosimo S, Gelber R, Moreno-Aspitia A. Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]. ESMO Open 2024, 9: 103938. PMID: 39418883, PMCID: PMC11532431, DOI: 10.1016/j.esmoop.2024.103938.Peer-Reviewed Original ResearchDisease-free survivalHER2-positive early breast cancerEarly breast cancerOverall survivalALTTO trialBreast cancerFollow-upMetastatic HER2-positive breast cancerDual anti-HER2 blockadeAnti-human epidermal growth factor receptor 2HER2-positive breast cancerEpidermal growth factor receptor 2Lapatinib to trastuzumabAnti-HER2 therapyAnti-HER2 blockadeTreatment groupsOutcomes of patientsAdjuvant trastuzumabOpen-labelAdjuvant chemotherapyPrimary endpointSecondary endpointsEfficacy analysisMulticenter studyAnti-HER2A Randomized Trial of Hypofractionated Post-Mastectomy Radiation Therapy (PMRT) in Women with Breast Reconstruction (RT CHARM, Alliance A221505)
Poppe M, Le-Rademacher J, Haffty B, Hansen E, Agarwal J, Wagner J, Kong I, Armer J, Arthur D, Whelan T, Lee M, Kour O, Lustberg M, Partridge A, Carey L, Ruddy K, Gaffney D, Stecklein S, Bernstein M, Khan A. A Randomized Trial of Hypofractionated Post-Mastectomy Radiation Therapy (PMRT) in Women with Breast Reconstruction (RT CHARM, Alliance A221505). International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s11. DOI: 10.1016/j.ijrobp.2024.07.002.Peer-Reviewed Original ResearchPost-mastectomy radiation therapyNeoadjuvant chemotherapyBreast reconstructionComplication rateReconstruction complicationsBreast cancerNon-inferiorityHigh-risk breast cancerBody mass index >Conventionally fractionated radiationGenetic predisposition genesImplant-only reconstructionsMedian Follow-UpImmediate breast reconstructionOne-sided type I errorNon-inferiority marginStandard of careHypofractionated radiationRegional recurrenceRadiation therapyTumor characteristicsInvasive BCAdjuvant chemotherapyPredisposition genesMedian ageImproved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)
Nowak J, Twombly T, Ma C, Shi Q, Haruki K, Fujiyoshi K, Väyrynen J, Zhao M, Knight J, Mane S, Shergill A, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Tan B, Philip P, O'Reilly E, Shields A, Ogino S, Fuchs C, Meyerhardt J. Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance). Journal Of Clinical Oncology 2024, 42: 2853-2859. PMID: 38889377, PMCID: PMC11392453, DOI: 10.1200/jco.23.01680.Peer-Reviewed Original ResearchDisease-free survivalStage III colon cancerIII colon cancerRisk of recurrenceGain-of-function mutationsColon cancerWildtype patientsMutation statusImproved survivalUsage of COX-2 inhibitorsGain-of-functionStandard adjuvant chemotherapyCOX-2Primary end pointCyclooxygenase 2 inhibitionCOX-2 inhibitorsColorectal cancer diagnosisCOX-2 inhibitionWhole-exome sequencing dataNational Cancer InstitutePIK3CA statusOverall survivalAdjuvant chemotherapyStatistically significant improvementClinical trial updateAdjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder Cancer
Koehne E, Bakaloudi D, Ghali F, Nyame Y, Schade G, Grivas P, Yezefski T, Hawley J, Yu E, Hsieh A, Montgomery R, Psutka S, Gore J, Wright J. Adjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder Cancer. Clinical Genitourinary Cancer 2024, 22: 102100. PMID: 38763862, DOI: 10.1016/j.clgc.2024.102100.Peer-Reviewed Original ResearchNational Cancer DatabaseAdjuvant chemotherapyReceipt of ACRadical cystectomyBladder cancerOverall survivalAssociated with significantly longer OSAssociated with OS benefitNon-metastatic bladder cancerMultivariate Cox regression analysisPrevalence of adenocarcinomaSquamous cell histologyMultivariate Cox regressionCox regression analysisMultivariate logistic regressionAssociated with lower oddsAssociated with greater oddsNeuroendocrine histologyLonger OSOS benefitCell histologyHistological subtypesCancer DatabaseClinicopathological featuresCox regressionProlonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection
Ying L, Ilagan-Ying Y, Kunstman J, Peters N, Almeida M, Blackburn H, Ferrucci L, Billingsley K, Khan S, Chhoda A, John N, Salem R, Sharma A, Ahuja N. Prolonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection. Surgical Oncology Insight 2024, 1: 100007. DOI: 10.1016/j.soi.2024.100007.Peer-Reviewed Original ResearchFactors associated with early mortalityCases of pancreatic adenocarcinomaPancreatic adenocarcinoma resectionRisk of early mortalityLength of stayEarly mortalityAdjuvant chemotherapyPancreatic adenocarcinomaChemotherapy utilizationAdenocarcinoma resectionRisk factors associated with early mortalityOmission of adjuvant therapyNon-metastatic pancreatic adenocarcinomaMultivariate Cox regression modelAssociated with early mortalityPost-resection survivalIncreased risk of early mortalityParticipant Use FileProlonged hospital stayProlonged length of stayAdjuvant chemotherapy utilizationDecrease perioperative complicationsCox regression modelsNon-academic centersHospital risk factorsConsensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective
Pashankar F, Murray M, Gell J, MacDonald N, Shamash J, Billmire D, Klosterkemper L, Olson T, Hirsch M, Lockley M, Stoneham S, Frazier A. Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective. EClinicalMedicine 2024, 69: 102453. PMID: 38544795, PMCID: PMC10965411, DOI: 10.1016/j.eclinm.2024.102453.Peer-Reviewed Original ResearchOvarian immature teratomaImmature teratomaElevated serum alpha-fetoproteinSurgery-only approachSerum alpha-fetoproteinOvarian ITStage IAAdjuvant chemotherapyRare neoplasmsOvarian cancerAdult patientsAlpha-fetoproteinLack of published dataPathologic interpretationPatient managementLow-gradeGrade 1Multiple subspecialtiesPatientsTeratomaYoung femalesAdult practiceNational advisory panelPaediatric teamGCTPrediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial
Krop I, Mittempergher L, Paulson J, Andre F, Bonnefoi H, Loi S, Loibl S, Gelber R, Caballero C, Bhaskaran R, Dreezen C, Menicucci A, Bernards R, van ’t Veer L, Piccart M. Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial. JCO Precision Oncology 2024, 8: e2200667. PMID: 38237097, DOI: 10.1200/po.22.00667.Peer-Reviewed Original ResearchConceptsInvasive disease-free survivalHER2 typeLuminal typeInvasive disease-free survival eventsHazard ratioEarly-stage breast cancerLuminal-type tumorsMolecular subtype signaturesAnti-HER2 therapyHER2-positive tumorsDisease-free survivalStandard adjuvant chemotherapyBasal-type tumorsBasal typePredictive of benefitAdjuvant pertuzumabAPHINITY trialHER2-typeHER2-positiveInferior prognosisAdjuvant chemotherapyTumor subtypesNo significant differenceAnti-HER2Breast tumors
2023
Falls prechemotherapy and toxicity‐related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial
Ji J, Bae M, Sun C, Wildes T, Freedman R, Magnuson A, O'Connor T, Moy B, Klepin H, Chapman A, Tew W, Dotan E, Fenton M, Kim H, Katheria V, Gross C, Cohen H, Muss H, Sedrak M. Falls prechemotherapy and toxicity‐related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial. Cancer 2023, 130: 936-946. PMID: 37962093, PMCID: PMC10922500, DOI: 10.1002/cncr.35105.Peer-Reviewed Original ResearchToxicity-related hospitalizationAdjuvant chemotherapyBreast cancerOlder womenPrimary end pointEarly breast cancerMultivariable logistic regressionGeriatric characteristicsGeriatric covariatesHOPE trialIncident hospitalizationGeriatric assessmentProspective studyGeriatric factorsHospitalizationChemotherapyGreater oddsStage IOlder personsEnd pointCancerLogistic regressionCategorical variablesWomenDiseaseMolecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay
Lin H, Can T, Kahn A, Flannery C, Hoag J, Akkunuri A, Bailey H, Baehner R, Pusztai L, Rozenblit M. Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay. The Oncologist 2023, 28: e973-e976. PMID: 37656608, PMCID: PMC10546821, DOI: 10.1093/oncolo/oyad249.Peer-Reviewed Original ResearchConceptsHER2 mRNA levelsIHC 0MRNA levelsOncotype DX recurrence score resultsEstrogen receptor-positive breast cancerReceptor-positive breast cancerCurrent adjuvant chemotherapyOncotype DX assayRecurrence Score resultsPositive breast cancerInvasive breast carcinomaIHC score 0Adjuvant chemotherapyQuantitative RT-PCRBreast carcinomaPositive statusScore 0Breast cancerStage IYale cohortHigher mRNA levelsCancerRT-PCRPatientsHER2Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848
Tchelebi L, Winter K, Abrams R, Safran H, Regine W, McNulty S, Wu A, Du K, Seaward S, Bian S, Aljumaily R, Shivnani A, Knoble J, Crocenzi T, DiPetrillo T, Roof K, Crane C, Goodman K. Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848. International Journal Of Radiation Oncology • Biology • Physics 2023, 118: 107-114. PMID: 37598723, PMCID: PMC10843017, DOI: 10.1016/j.ijrobp.2023.08.014.Peer-Reviewed Original ResearchConceptsTarget volumeRadiation therapy quality assuranceRadiation therapyPlanning target volumeClinical treatment volumeGross target volumePretreatment QAContouring atlasTreatment planningResectable pancreatic head adenocarcinomaRT planningIntensity modulated RTQA analysisPancreatic head adenocarcinomaNRG Oncology RTOGPracticing radiation oncologistsReal-time quality assuranceTreatment volumeEffects of RTConcurrent fluoropyrimidineConformal RTAdjuvant chemotherapyRadiation oncologistsQuality assurancePancreas cancerOverall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).
Herbst R, Tsuboi M, John T, Kato T, Majem M, Grohé C, Wang J, Goldman J, Lu S, Su W, de Marinis F, Shepherd F, Lee K, Le N, Dechaphunkul A, Kowalski D, Poole L, Stachowiak M, Rukazenkov Y, Wu Y. Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2023, 41: lba3-lba3. DOI: 10.1200/jco.2023.41.17_suppl.lba3.Peer-Reviewed Original ResearchNon-small cell lung cancerStage IB-IIIA non-small cell lung cancerAdjuvant osimertinibOverall survival analysisOS HRAdjuvant chemotherapyOS benefitOS ratesII-IIIASurvival analysisDisease-free survival benefitFinal overall survival analysisGlobal phase III studyEGFR T790M resistance mutationII-IIIA diseaseStage IB-IIIAT790M resistance mutationTolerable safety profilePhase III studyCell lung cancerComplete tumor resectionEGFR-TKI sensitizingM resistance mutationExtended treatment durationADAURA studyOverall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Tsuboi M, Herbst R, John T, Kato T, Majem M, Grohé C, Wang J, Goldman J, Lu S, Su W, de Marinis F, Shepherd F, Lee K, Le N, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu Y. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. New England Journal Of Medicine 2023, 389: 137-147. PMID: 37272535, DOI: 10.1056/nejmoa2304594.Peer-Reviewed Original ResearchConceptsDisease-free survivalOverall survivalIIIA diseaseStage IBAdjuvant osimertinibPlacebo groupOsimertinib groupNew serious adverse eventsSignificant overall survival benefitStage IILonger disease-free survivalEnd pointData cutoff datePrevious adjuvant chemotherapyDouble-blind trialOverall survival benefitPrimary end pointSecondary end pointsSerious adverse eventsCell lung cancerCoronavirus disease 2019Epidermal growth factor receptorADAURA trialAdjuvant chemotherapyEligible patientsAdjuvant chemotherapy does not improve outcome in children with ovarian immature teratoma: A comparative analysis of clinical trial data from the Malignant Germ Cell International Consortium
Vieira A, Puthenpura V, Krailo M, Fallahazad N, Brougham M, Murray M, Frazier A, Lopes L, Pashankar F. Adjuvant chemotherapy does not improve outcome in children with ovarian immature teratoma: A comparative analysis of clinical trial data from the Malignant Germ Cell International Consortium. Pediatric Blood & Cancer 2023, 70: e30426. PMID: 37243320, DOI: 10.1002/pbc.30426.Peer-Reviewed Original ResearchConceptsOvarian immature teratomaOverall survivalImmature teratomaPostoperative chemotherapyBrazilian patientsStage IIAdjuvant chemotherapyUK cohortGrade 1 diseaseGrade 3 patientsReceipt of chemotherapyMainstay of therapyValue of chemotherapyPrimary outcome measureClinical trial dataIT patientsEntire cohortUK patientsRelapse riskBrazilian cohortOutcome measuresPractice variationChemotherapyPatientsStage I
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply